FDA-Approved Minimum Age for Methotrexate
Methotrexate is FDA-approved for children as young as 2 years old for juvenile idiopathic arthritis (JIA), with dosing starting at 10 mg/m² weekly.[1] For polyarticular JIA specifically, approval covers ages 2 and up based on clinical trials showing efficacy and safety.[2]
Use in Infants Under 2 Years
Off-label use occurs in infants under 2 for severe conditions like infantile acute lymphoblastic leukemia (ALL), where it's part of multi-agent chemotherapy regimens. No strict minimum age exists here, but dosing adjusts by body surface area, and risks like myelosuppression require close monitoring.[3] Pediatric oncology guidelines support this from birth in life-threatening cases.[4]
Minimum Age by Condition
- Rheumatoid arthritis and psoriasis: Approved for adults 18+; pediatric use off-label under specialist guidance.[1]
- Cancer (e.g., leukemia, lymphoma): Used from infancy or neonatal period in high-dose protocols, often with leucovorin rescue.[3]
- Ectopic pregnancy: Adults only (typically 18+), as it's not indicated for pediatric patients.[1]
Why Age Limits Vary
Regulatory approvals stem from trial data; JIA trials excluded under-2s due to ethical concerns over toxicity, but cancer protocols include neonates because benefits outweigh risks in acute settings. High-dose methotrexate clears via kidneys, so immature renal function in newborns demands dose reductions.[4]
Safety Concerns for Young Patients
Common issues in kids include nausea, stomatitis, and liver enzyme elevations, with higher myelotoxicity risks under age 2. Weekly low-dose regimens (under 15 mg/m²) are safer for JIA than high-dose cancer use. Folic acid supplementation reduces side effects across ages.[2][3] Always requires baseline labs and monitoring.
[1]: FDA Label for Methotrexate (Rheumatrex)
[2]: American College of Rheumatology JIA Guidelines
[3]: NCCN Pediatric ALL Guidelines
[4]: UpToDate: Methotrexate in Pediatrics